Do the benefits really outweigh the risks when it comes to the use of thrombolytic drugs for central retinal artery occlusion (CRAO)? Drs. Amanda Henderson and Michael Carper weigh in on the recently published Tenecteplase in Central Retinal Artery Occlusion Study (TenCRAOS) and how ophthalmologists should proceed in their management of CRAO with tenecteplase (TNK) or another tissue plasminogen activator (tPA).

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

With an abundance of therapeutic options for managing diabetic macular edema (DME), what patient characteristics inform your treatment decisions? Does the number of loading doses influence long-term macular fluid outcomes? How are you managing insurance-mandated step-therapy in your patients? In today's episode, host Dr. Jay Sridhar invites Drs. Durga Borkar and Carl Danzig to share how they've integrated new anti-VEGF therapies into clinical practice.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Is the Merit-based Incentive Payment System (MIPS) fulfilling its intended purpose, or is it just causing headaches? Dr. George Williams and Joe Reyes join host Dr. Andrew Pouw to share their expertise and experience with MIPS, including its evolution from prior medical cost control policies and how ophthalmologists can use the IRIS Registry to meet reporting requirements.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts